Hepatic Form of Dihydrolipoamide Dehydrogenase Deficiency ( DLDD ): Phenotypic Spectrum, Laboratory Findings, and Therapeutic Approaches in 52 Patients
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.70035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Nicole Hammann und 18 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg University, Medical Faculty, University Hospital Heidelberg, Center for Child and Adolescent Medicine, Division of Pediatric Neurology and…. Hauptthemen laut MEDLINE: Dihydrolipoamide Dehydrogenase, Mitochondrial Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dietmar Hopp Foundation, Austrian Science Fund, Dietmar Hopp Stiftung.
Abstract (Originalsprache)
Dihydrolipoamide dehydrogenase deficiency (MIM 246900/DLDD) is an autosomal recessive mitochondrial disease with three clinical subgroups. The hepatic form leads to recurrent metabolic decompensations often accompanied by elevated levels of liver transaminases (ELT) in blood, sometimes progressing to acute liver failure (ALF). Genetically, it is linked to the p.G229C variant in the DLD gene, which has been reported in the Ashkenazi Jewish and Arabic population. In this study, we analyzed phenotypic diversity, therapeutic management, and outcome in novel symptomatic individuals with hepatic DLDD identified by whole exome sequencing ( n = 7) in Central Europe as well as in previously reported cases ( n = 45). Fifty‐one of 52 DLDD patients carried the p.G229C variant (39 in a homozygous state). During decompensations, precipitated by febrile infectious disease or fasting, affected individuals presented with nausea, vomiting, abdominal pain, hepatomegaly, hypoglycemia, and lactic acidosis. In individuals homozygous for the p.G229C variant, neurologic manifestations were rare, whereas mild neurologic symptoms were found in individuals ( n = 8) carrying a different DLD variant in trans . During decompensation, levels of specific plasma amino acids like citrulline or branched‐chain amino acids, and urinary organic acids, like 2‐oxoglutaric acid, were frequently elevated. However, known biomarkers—with the exception of lactate—were not consistently elevated during these episodes and typically normal in the interval, highlighting the usefulness of early genetic testing in all children with unexplained ELT or ALF to reduce the time to diagnosis. While there exists consensus for rescue therapy with intravenous glucose during decompensations and maintenance therapy with riboflavin, therapies with thiamine and antioxidants (e.g., N‐acetylcysteine) were reported to be useful in single individuals with recurrent decompensations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heidelberg University, Medical Faculty, University Hospital Heidelberg, Center for Child and Adolescent Medicine, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg, Germany.
- Institute of Human Genetics, School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Institute of Human Genetics, Helmholtz Zentrum Munich, Neuherberg, Germany.
- Bókay Street Department, Pediatric Centre, Semmelweis University, Budapest, Hungary.
- University Children's Hospital, Salzburger Landeskliniken (SALK) and Paracelsus Medical University (PMU), Salzburg, Austria.
- University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland.
ORCID-Profile: Nicole Hammann, Christian Staufner, René G Feichtinger, Johannes A Mayr, Stefan Kölker, Georg F Hoffmann, Dominic Lenz
Förderung
- Dietmar Hopp Foundation
- Austrian Science Fund
- Dietmar Hopp Stiftung
Zitieren
APA
Hammann, N., Staufner, C., Schlieben, L. D., Dezsőfi-Gottl, A., Feichtinger, R. G., Häberle, J., Junge, N., Konstantopoulou, V., Kopajtich, R., McLin, V., Rymen, D., Slavetinsky, C., Sturm, E., Mayr, J. A., Wagner, M., Kölker, S., Prokisch, H., Hoffmann, G. F., & Lenz, D. (2025). Hepatic Form of Dihydrolipoamide Dehydrogenase Deficiency ( DLDD ): Phenotypic Spectrum, Laboratory Findings, and Therapeutic Approaches in 52 Patients. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70035
Vancouver
Hammann N, Staufner C, Schlieben LD, Dezsőfi-Gottl A, Feichtinger RG, Häberle J, et al. Hepatic Form of Dihydrolipoamide Dehydrogenase Deficiency ( DLDD ): Phenotypic Spectrum, Laboratory Findings, and Therapeutic Approaches in 52 Patients. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70035
BibTeX
@article{Hammann2025,
author = {Hammann, Nicole and Staufner, Christian and Schlieben, Lea Dewi and Dezsőfi-Gottl, Antal and Feichtinger, René G and Häberle, Johannes and Junge, Norman and Konstantopoulou, Vassiliki and Kopajtich, Robert and McLin, Valérie and Rymen, Daisy and Slavetinsky, Christoph and Sturm, Ekkehard and Mayr, Johannes A and Wagner, Matias and Kölker, Stefan and Prokisch, Holger and Hoffmann, Georg F and Lenz, Dominic},
title = {Hepatic Form of Dihydrolipoamide Dehydrogenase Deficiency ( DLDD ): Phenotypic Spectrum, Laboratory Findings, and Therapeutic Approaches in 52 Patients},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.70035}
}
EUVIMED